Prime Minister’s Advisor reveals plans to produce fifty percent of imported medicines

Baghdad-INA  
The Prime Minister's Advisor for Pharmaceutical Industry Affairs, Hamoudi Al-Lami, revealed today, Sunday, the advantages of the pharmaceutical industry localization project, while indicating the desire of investors to establish factories in Iraq, with plans to produce fifty percent of medicines.
 
 
 
Al-Lami said, to the Iraqi News Agency (INA), that "the start of the project to localize the pharmaceutical industry took place from the first moment of the Cabinet's decision," stressing "the desire of many investors to establish pharmaceutical factories in Iraq."
 
He explained, "There are 24 private pharmaceutical factories, in addition to the Samarra Pharmaceutical Company, there is also a joint Arab company that produces antibiotics. It has begun to develop plans to develop its programs, add production lines, and improve its production, in addition to 24 factories under construction."
 
Al-Lami indicated, “Prime Minister Muhammad Shia’ al-Sudani visited one of the factories that was established during the Corona period and is specialized in the production of antiseptics, sterilizers, dialysis solutions, and some wine materials that are used in hospitals and operating theaters, and according to the decisions that were taken recently to localize the pharmaceutical industry, contacts were made with international companies, Including Pax, which is considered No. 1 in the production of dialysis solutions and intravenous solutions, and in the coming weeks, a technology transfer agreement will be signed in stages and within two years.
 
Al-Lami confirmed that "Samarra Pharmaceutical Company has been working with high quality for decades," noting that "Samarra's medicines and national factories were not competitive with imported medicines, especially since they are imported from abroad for unreliable companies, poor quality, and low prices, and this is one of the reasons for the dumping of the market and the lack of development of the industry medication during the last period.”